Cancer Stage-Specific Treatment Selection / 癌症分期与治疗选择

Definition

Cancer stage-specific treatment selection is the matching of observation, local treatment, surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and supportive care to tumor type, pathology, stage, anatomy, biomarkers, patient condition, and goals.

Current Synthesis

VOL.21 dismantles the imagined fixed sequence “cancer, surgery, chemotherapy, radiotherapy, death.” Early localized disease may sometimes be removed and followed without systemic treatment. Other disease may need radiotherapy, chemotherapy, targeted therapy, immunotherapy, or combinations, and selected systemic treatment can sometimes reduce disease enough to reopen a surgical option. The modality name therefore says little without the indication and treatment goal.

The source also distinguishes mature, tumor-specific evidence from possibility. Targeted medicines require an actionable feature and do not avoid all off-target effects. Gene testing may help selected patients identify options, but it does not guarantee an effective drug. Immunotherapy changes immune recognition rather than merely “boosting immunity,” and suitability, toxicity, and response remain patient- and tumor-specific.

Key Claims

• Cancer treatment is selected by diagnosis, pathology, stage, anatomy, molecular features, patient condition, and goals rather than by a universal ladder.
• Some early tumors can be treated locally and monitored without chemotherapy or radiotherapy.
• Surgery remains important for many solid tumors but requires an indication and adequate patient and anatomical conditions.
• Systemic or local treatment can sometimes convert previously inoperable disease into a surgical candidate, but this is not guaranteed.
• Targeted therapy requires a meaningful target, and testing does not ensure that a mature or effective drug exists.
• Immunotherapy, chemotherapy, and radiotherapy have distinct mechanisms and burdens; none is synonymous with inevitable terminal decline.

Evidence

• Modality separation: VOL.21 distinguishes radiotherapy, chemotherapy, targeted therapy, immunotherapy, surgery, and surveillance by cancer type and stage.
• Early-treatment boundary: VOL.21 notes that selected early tumors may need local removal and follow-up rather than automatic adjuvant treatment.
• Conversion possibility: VOL.21 describes targeted or immune treatment as sometimes creating later surgical conditions.

Counterevidence & Qualifications

The source provides no staging system, guideline, trial evidence, biomarker protocol, comparative-effectiveness data, or toxicity-management pathway. Its claims about hepatobiliary radiotherapy, the number of cancers with mature targets, gene testing, PD-1, treatment conversion, and small-lesion surveillance are broad and source-dated. Treatment decisions require current multidisciplinary assessment and informed patient participation; public education cannot determine an individual plan.

What Changed

• Created a general indication- and stage-specific frame that separates cancer diagnosis from an automatic treatment sequence.

Related Concepts

• Tumor Terminology and Malignancy Boundary / 肿瘤术语与恶性判断边界 - establishes what must be diagnosed before treatment is selected.
• Liver-Cancer Screening and Treatment Selection - applies multimodal selection to liver cancer and liver reserve.
• Biliary Cancer Decision and Prognosis Boundary / 胆道肿瘤决策与预后边界 - applies anatomy, pathology, and stage to biliary disease.
• Lung Cancer Multimodal Treatment / 肺癌多模式综合治疗 - cancer-specific example of combined local and systemic care.
• Clinical Outcome Uncertainty / 临床结局不确定性 - prevents treatment choice from becoming a guaranteed outcome.
• Medical Risk Management - supplies the broader benefit, harm, and inaction framework.